MDMA Therapy for PTSD: Promising Results, Uncertain Evidence
A 2026 review and meta-analysis of six randomized trials involving 286 people found that MDMA-assisted therapy improved PTSD symptoms in the short term and more than doubled the likelihood of remission. However, the authors rated the evidence as low certainty because blinding was difficult and all trials shared the same sponsor and related therapy protocols. Further studies by the VA and independent researchers are testing different therapies, groups, and doses, while FDA approval remains uncertain.
PTSD affects roughly 8% of U.S. adults during their lifetime, with higher rates among some veterans; Gulf War veterans may reach 21%. An October 2026 Neuropsychopharmacology review by Brooke Sevchik and former Penn colleagues pooled six randomized trials with 286 participants. It found short-term symptom improvement and more than doubled remission odds from MDMA-assisted therapy.
Yet certainty was low: participants often recognize MDMA, complicating blinding, and all six trials shared MAPS sponsorship and similar therapy protocols. The FDA declined approval in August 2024; Resilient Pharmaceuticals, formerly Lykos, resubmitted in August 2026. VA and independent researchers are testing different therapies, groups, and doses.
Patients with PTSD, especially veterans, may face difficult choices if a promising treatment remains unproven. Clinicians and regulators could be pressed to balance access with safety and informed consent. Positive coverage may raise expectations, while low-certainty evidence might slow insurance coverage or guideline adoption. Independent trials could clarify who benefits and how, potentially shaping mental-health care, research priorities, and public trust in psychedelic medicine.